Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases

Microbiology and Infectious Diseases Department, Royal Women's Hospital, and the University of Melbourne, Melbourne, Australia.
New England Journal of Medicine (Impact Factor: 55.87). 06/2007; 356(19):1928-43. DOI: 10.1056/NEJMoa061760
Source: PubMed


A phase 3 trial was conducted to evaluate the efficacy of a prophylactic quadrivalent vaccine in preventing anogenital diseases associated with human papillomavirus (HPV) types 6, 11, 16, and 18.
In this randomized, placebo-controlled, double-blind trial involving 5455 women between the ages of 16 and 24 years, we assigned 2723 women to receive vaccine and 2732 to receive placebo at day 1, month 2, and month 6. The coprimary composite end points were the incidence of genital warts, vulvar or vaginal intraepithelial neoplasia, or cancer and the incidence of cervical intraepithelial neoplasia, adenocarcinoma in situ, or cancer associated with HPV type 6, 11, 16, or 18. Data for the primary analysis were collected for a per-protocol susceptible population of women who had no virologic evidence of HPV type 6, 11, 16, or 18 through 1 month after administration of the third dose.
The women were followed for an average of 3 years after administration of the first dose. In the per-protocol population, those followed for vulvar, vaginal, or perianal disease included 2261 women (83%) in the vaccine group and 2279 (83%) in the placebo group. Those followed for cervical disease included 2241 women (82%) in the vaccine group and 2258 (83%) in the placebo group. Vaccine efficacy was 100% for each of the coprimary end points. In an intention-to-treat analysis, including those with prevalent infection or disease caused by vaccine-type and non-vaccine-type HPV, vaccination reduced the rate of any vulvar or vaginal perianal lesions regardless of the causal HPV type by 34% (95% confidence interval [CI], 15 to 49), and the rate of cervical lesions regardless of the causal HPV type by 20% (95% CI, 8 to 31).
The quadrivalent vaccine significantly reduced the incidence of HPV-associated anogenital diseases in young women. (ClinicalTrials.gov number, NCT00092521 [ClinicalTrials.gov].).

Download full-text


Available from: Diane M Harper,
  • Source
    • "Recently, the use of noninfectious viruslike particles (VLPs) that self-assemble by spontaneous interactions of viral structural proteins has been suggested and developed as alternative approaches for developing advanced vaccines for a wide range of viruses that cause disease in humans (Roy and Noad 2009; Kang et al. 2009a; Kang et al. 2009b). It is worth noting that a VLP-based human papillomavirus (HPV) vaccine against HPV responsible for cervical cancer was produced in the yeast system and approved for the market in 2006 (Garland et al. 2007). Influenza VLPs expressed by recombinant baculovirus (rBV) systems that present multi-component antigens, including HA and matrix 1 (M1), with or without NA, and that are capable of inducing cognate responses against homologous strains of influenza virus have been widely "
    [Show abstract] [Hide abstract]
    ABSTRACT: Natural infection and then recovery are considered to be the most effective means for hosts to build protective immunity. Thus, mimicking natural infection of pathogens, many live attenuated vaccines such as influenza virus, and yellow fever vaccine 17D were developed and have been successfully used to induce protective immunity. However, humans fail to generate long-term protective immunity to some pathogens after natural infection such as influenza virus, respiratory syncytial virus (RSV), and human immunodeficiency virus (HIV) even if they survive initial infections. Many vaccines are suboptimal since much mortality is still occurring, which is exampled by influenza and tuberculosis. It is critically important to increase our understanding on protein components of pathogens and vaccines as well as cellular and host responses to infections and vaccinations. Here, we highlight recent advances in gene transcripts and protein analysis results in the systems biology to enhance our understanding of viral pathogens, vaccines, and host cell responses.
    12/2015; 6(1). DOI:10.1186/s40543-015-0047-4
  • Source
    • "HPV infection and its consequences are potentially preventable with an HPV vaccine [Palefsky et al., 2011]. The efficacy of the quadrivalent (4vHPV) vaccine (covers HPV 6, 11, 16, and 18) against cervical cancer or cervical intraepithelial neoplasia (CIN) among women aged 16–26 years was almost 100% [Garland et al., 2007]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: HPV DNA testing is receiving increasing popularity in cervical cancer screening. There is a lack of universal guidelines on HPV testing. Our study aimed to assess age-specific and year-on-year trend of HPV positivity and incidence and HPV retesting among 26,457 individual women attending the gynecological department at the First People's Hospital of Yunnan Province (FPHY) who had an HPV testing between January 1, 2012 and December 31, 2014. HPV types 16, 52, cp8304, 58 and 6 ranked top 5 with regard to positivity in each year and overall incidence. The positivity of various HPV types peaked among women aged 15-19 years, then sharply decreased with age, stabilized among women aged 25-49 years and then surged again among women aged 50 years and older. The positivity of high-risk(HR) HPV types, including HPV 16, 18, 31, 33, 56 and 58, were on the rise during the time period (p<0.05 for all). HR HPV types tended to be more likely to persist than LR HPV types (p<0.05). Additionally the incidence rate for any HR HPV type was also significantly higher than that for any LR HPV type (42.8 vs 12.6 per 100 person-years, p<0.001). The majority (57.3-77.5%) of women detected with HR HPV types did not retest within 12 months. Clinical guidelines on HPV DNA testing are needed and education, and counseling about HPV infection and its implications for women detected with HPV at clinical settings, are warranted.
    Journal of Medical Virology 09/2015; DOI:10.1002/jmv.24377 · 2.35 Impact Factor
  • Source
    • "Taking cultural differences into account, parental attitude toward HPV vaccination for boys and girls in China could be different in comparison to findings from other countries. HPV vaccines have been proved to be efficient in preventing HPV infection both in men and women [2] [3]. Therefore, the World Health Organization and the U. S. Centers for Disease Control and Prevention has recommended HPV vaccines for use in both young females and males before the onset of sexual activity [17] [18] [19]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: To determine the level of awareness on human papillomavirus (HPV) vaccine and acceptance of HPV vaccination among parents of junior middle school students. A cross sectional survey employing cluster sampling was conducted in Jinan, Shandong Province of China in January of 2013. A total of 400 parents of junior middle school students participated in the questionnaire survey, among whom 360 (90%) completed valid questionnaires. About 22 (22.5%) parents had ever heard of HPV. Only one in ten (10.2%) knew about HPV vaccine. Parents willing to accept HPV vaccination for children accounted for 40.8%. Factors associated willing to accept HPV vaccination for children among parents were: female parent (AOR: 0.38, 95%CI: 0.21-0.67), having ever heard of HPV vaccine (AOR: 2.38, 95%CI: 1.01-5.60), thinking HPV vaccination should commence before sexual debut(AOR: 2.16, 95%CI: 1.21-3.85), thinking HPV vaccination should commence before 12 years old (AOR: 2.76, 95%CI: 1.02-7.46) or 13-15 years old (AOR: 4.75, 95%CI: 1.79-12.61), concern about suffering from cervical cancer and/or genital warts (AOR: 2.43, 95%CI: 1.31-4.50). About 60% of parents were in favor of future HPV vaccination promoting in China believing that HPV vaccine could efficiently prevent cervical cancer, anal cancer or genital warts, 37.4% of parents with expectation of governmental subsidy and price regulation. Parental awareness level of HPV vaccine and willingness to accept HPV vaccination for children was low. However, the general attitude of many participants toward future promoting of HPV vaccination in China was encouraging, particularly if certain expectations were met. Copyright © 2015. Published by Elsevier Ltd.
    Vaccine 04/2015; 33(22). DOI:10.1016/j.vaccine.2015.04.010 · 3.62 Impact Factor
Show more